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Neuroendocrine tumors (NETs) of the diffuse neuroendocrine 
system (neuroendocrine cells spread as a single cell or as clusters of 
cells throughout the gastrointestinal tract, the bronchopulmonary 
system, and the urogenital tract), are often referred to as carcinoids. 
NETs occur most frequently in the gastrointestinal tract (66%), with the 
second most common location in the bronchopulmonary system (31%), 
followed by less frequent locations including the ovaries, testes, 
hepatobiliary system, and pancreas [3]. Carcinoids can be both sporadic 
(nonfamilial) or part of familial syndromes such as multiple endocrine 
neoplasia, von Hippel–Lindau syndrome, and neurofibromatosis [5]. The 
tumors tend to be slow-growing, small (although aggressive variants 
exist) and often present a considerable diagnostic and therapeutic 
challenge due to lack of symptoms until they metastasize.. The majority 
of tumors are thus diagnosed at a stage at which the only curative 
treatment, radical surgical intervention, is no longer an option. Long-
acting somatostatin analogues are often effective in ameliorating 
symptoms but have no effect on tumor growth, and specific tumor-
targeted treatments with predictable curative efficacy are lacking. As 
many as 15–25% of NETs exhibit a synchronous or metachronous 
association with other tumors (usually adenocarcinomas , commonly 
located in the colon) [6]. This probably reflects the activity of growth 
factors produced by the tumors that promote phenotypic changes in 
susceptible cells and induce neoplastic transformation [6,7]. A relatively 
large percentage of gastrointestinal NETs are multicentric (2% overall 
but as high as 33% in the small bowel), supporting the thesis that a 
common local growth factor or initiating event may influence similar 
progenitorcells in different locations [4,8]. 
 
2. Risk factors for neuroendocrine cancer 
 People with multiple endocrine neoplasia type 1 (MEN 1) syndrome 
develop multiple endocrine and neuroendocrine tumours. 
 Multiple endocrine neoplasia type 2 (MEN 2) syndrome is associated 
with many endocrine tumours, such as pheochromocytoma. A tumour 
that starts in an adrenal gland (the glands on top of each kidney that 
release hormones to help control heart rate and blood 
pressure) and medullary thyroid carcinoma. 
 Von Hippel-Lindau syndrome is an inherited familial cancer 
syndrome. People with this disorder may develop a variety of 
neuroendocrine tumours, including pheochromocytoma and 
pancreatic endocrine (islet cell) tumours. 
 Tuberous sclerosis is a genetic disorder that causes benign tumours 
to form in many organs of the body, including the eyes, skin, brain, 
lungs, heart and kidneys. People with tuberous sclerosis also have an 
increased risk of developing neuroendocrine tumours. 
 
Neurofibromatosis:  
A genetic condition that affects the nervous system. It affects 
the development and growth of neurons (nerve cells), causes tumours 
(neurofibromas) to grow on nerves and may produce other 
abnormalities in muscles, bones and skin. type 1 (von Recklinghausen 
disease) causes many neurofibromas (benign tumours that form in 
nerves) to occur. Neuroendocrine tumours of the pancreas and small 
intestine are more common in people diagnosed with neurofibromatosis 
type 1. Tobacco smoke- Small cell lung cancer (SCLC) and large cell 
neuroendocrine carcinoma (LCNEC) are neuroendocrine carcinomas 
that develop in the lungs. These tumours are strongly associated with 
tobacco smoking. Neuroendocrine tumours of the larynx may also be 
associated with tobacco smoke. Some types of neuroendocrine tumours 
are more common in people with a family history of neuroendocrine 
tumours or other types of cancer. 
 
3. Classification 
The traditional classification of carcinoids, based on their 
embryonic origin, comprises the foregut (lung, thymus, stomach, 
pancreas and duodenum), midgut (from the duodenum beyond the 
Treitz ligament to the proximal (transverse colon) and hindgut 
carcinoids (distal colon and rectum) [9]. Although this archaic 
classification is still used, a tumor-based classification introduced by the 
World Health Organization in 2000 has far greater applicability [10]. 
The latter classification utilizes the more generic term, neuroendocrine 
tumor, and tumor classification is based upon size, proliferative rate, 
localization, differentiation and hormone production. Distinction is 
made between well differentiated NETs (benign behaviour or uncertain 
malignant potential), well differentiated neuroendocrine carcinomas 
(low-grade malignancy), and poorly differentiated (usually small cell) 
neuroendocrine carcinomas of high-grade malignancy. The term 
carcinoid was not completely discarded, and it is used synonymously 
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with the term ‘well differentiated NET’. The current basis of lung NET 
classification produced by the World Health Organization (2004) is a 
histological classification system comprising four subtypes of tumors: 
the low-grade typical carcinoid, the intermediate-grade atypical 
carcinoid (both classified as bronchopulmonary carcinoids), and the two 
high-grade large-cell neuroendocrine carcinoma and small-cell lung 
carcinoma.. 
The World Health Organization diagnostic criteria for a 
typical carcinoid are: a tumor with carcinoid morphology and less than 
2 mitoses/2mm2 (10 HPH), lacking necrosis and 0.5 cm or larger. An 
atypical carcinoid is defined as a tumor with carcinoid morphology with 
2–10 mitoses/2mm2 and/or necrosis (often punctuate). 
 
4. Clinical manifestations 
In hormonally active tumors, variable symptoms maydevelop 
depending on the tumor cell of origin and theeffects of secreted 
bioactive substances (serotonin, catecholamine, dopamine, histamine, 
gastrin, glucagon, prostaglandins, among others). The classical carcinoid 
syndrome is relatively uncommon (20% of small bowel NETs, <5% for 
NETs of other locations), typically consisting of diarrhea, cutaneous 
flushing, broncho-constriction. Gastrointestinal NETs may present with 
emergency clinical symptoms (3–5%) such as acute 
abdomen(obstruction, perforation, bleeding) and abdominal angina 
(major vessel compromise), which arise due either to local tumor mass 
effects or tumor-induced fibrosis .The majority of patients, 58% with 
bronchopulmonary carcinoids, are symptomatic at presentation, and the 
most common symptoms – cough 32%, hemoptysis 26%, and 
pneumonia 24% (the classical triad) – represent the effects of luminal 
obstruction and ulceration of the tumor  . Cushing’s syndrome may 
occur as a paraneoplastic phenomenon (ectopic production and 
secretion of adrenocorticotrophic hormone) associated with 
bronchopulmonary carcinoids in approximately1–2% of patients.  
 
5. Biochemical markers 
Measurement of urinary 5-hydroxyindole-3-acetic acid, the 
degradation product of serotonin, has a specificity of 88% for serotonin-
producing NETs, although tryptophan-rich foods (bananas, avocados, 
plums, eggplant, tomatoes, plantain, pineapples and walnuts) can 
providefalse elevations. Overnight 5-hydroxyindole-3-acetic acid 
collection may be as sensitive as a 24-h collection in identifying patients 
with serotonin-producing tumors. Higher concentrations of urinary 5-
hydroxyindole-3-acetic acid are consistent with a worse prognosis. 
Chromogranin A is a water-soluble acidic glycoprotein stored in the 
secretory granules of NETs and can beutilized as a general plasma 
tumor marker for gastrointestinal NETs as well as ‘nonfunctioning’ 
tumors. Although plasma chromogranin A levels are very sensitive 
(99%) markers of NETs, they are nonspecific as they are also elevated in 
other tumor types, such as small-cell lung carcinoma, and even some 
prostate carcinomas. In addition to the diagnostic value, however, 
plasma chromogranin A levels are also well correlated to tumor volume 
and burden. 
                            Recent studies suggest that alkaline phosphatase and 
neurokinin A are better predictors of survival in metastatic NETs than 
chromogranin A. Other markers including serotonin, histamine, gastrin, 
vasoactive intestinal peptide, glucagon, bradykinin, substance P, 
neurotensin, human chorionic gonadotrophin, neuropeptide K, 
neuropeptideL and pancreatic polypeptide are of value in precisely 
defining the functionality of individual NETs. Histochemical indicators of 
prognosis include the degree of expression of the proliferation marker 
Ki-67 and the p53 tumor suppressor protein. 
                                             
 
6. Topographic localization 
Upper gastrointestinal endoscopy can identify lesions to the 
level of the ligament of Treitz, and colonoscopy can detect terminal ileal 
tumors as well as colon and rectal NETs. Endoscopic ultrasound is a 
highly sensitive method for diagnostic and preoperative evaluation of 
NETs of thestomach, duodenum, pancreas and rectum since it not only 
identifies submucosal lesions but it also facilitates staging.   Flexible 
fiberoptic bronchoscopy is the most effective technique for the 
diagnosis and treatment of a variety of bronchopulmonary carcinoids 
and tumor-targeted radioactive treatment with radiolabeled 
somatostatin analogues. Positron emission tomography (PET) detects 
accumulation of radiolabeled biological substances such as 
18Ffluorodeoxyglucose and the radiolabeled precursor of serotonin 
synthesis, 11C-5-hydroxytryptopha 
Neuroendocrine tumours of the endocrine system- 
These tumours start in the neuroendocrine cells of various 
endocrine glands: Pituitary adenoma ,thyroid medullary carcinoma, 
thymus neuroendocrine cancer, parathyroid neuroendocrine cancer, 
pheochromocytoma, paraganglioma. 
Neuroendocrine tumours of unknown primary 
Most people diagnosed with neuroendocrine carcinoma of 
unknown primary (CUP) have advanced disease. They will need 
aggressive treatment to reduce the tumours as much as possible. Rarely, 
neuroendocrine carcinomas can occur elsewhere in the body, including 
the breast, kidney, urinary bladder and prostate. Other rare 
neuroendocrine disorders include multiple endocrine neoplasia (MEN) 
syndromes - genetic disorders that usually cause multiple tumours to 
develop in the endocrine glands. Once the type of tumour has been 
diagnosed, the doctor will also consider: ,the functional status (if the 
tumour is releasing hormones or not) and type of hormone released, the 
frequency and severity of symptoms caused by too much of a particular 
hormone, the grade of the tumour (how abnormal the cancer cells look 
and behave), the stage of the cancer, including if it has spread 
(metastasized) and where it has spread, evidence of any complications, 
such as carcinoid-related heart disease, prognostic factors (special 
characteristics that might influence the course of the disease), survival 
statistics for the particular type and stage of cancer. 
 
7. Laryngeal Neuroendocrine Cancers 
Benign-Laryngeal paraganglioma 
Malignant: 
Typical carcinoid (well diffd), Atypical carcinoid (Mod diffd), 
Small cell neuroendocrine (poorly diffd), Conbined small cell 
neuroendocrine carcinoma, Large cell neuroendocrine carcinoma
  
Salivary gland- 
1. Neuroendocrine type 
a) Merkel cell subtype 
b) Pulmonary subtype 
2. Ductal type 
Gastrointestinal and pancreatic neuroendocrine tumours and 
carcinomas 
Gastrointestinal  and pancreatic neuroendocrine tumours are 
together called gastroenteropancreatic (GEP) neuroendocrine tumours. 
This is the largest group of neuroendocrine tumours and includes: well-
differentiated neuroendocrine tumours,well-differentiated 
neuroendocrine carcinoma,poorly differentiated neuroendocrine 
carcinoma. They can develop in the following areas of the 
gastrointestinal tract:-pancreas, small intestine, appendix, large 
intestine (colon and rectum), stomach, esophagus (rare site of 
neuroendocrine tumours).  
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Gastrointestinal and pancreatic neuroendocrine tumours and 
carcinomas are named based on the type of cell they develop in and the 
hormones the tumours produce:serotonin-producing neuroendocrine 
tumours or carcinomas, insulinoma, gastrinoma, VIPoma, glucagonoma 
somatostatinoma, ACTHoma, PPoma and non-functioning. 
 
Gastric neuroendocrine tumors 
Gastric NETs account for<2 % of all gastric malignancies, 9% of NETs, and the incidence/prevalence is increasing [2]. 
 
Table 1: WHO typing of gastric NET 
 
 Type 1 Type 11 Type III Type IV 
Preexisting condition Gastritis  
of corpus 
Zollinger 
 Ellison  (MEN1) 
None  
sporadic 
Gastric parietal cell  
acid secreting dysfunction 
Hypergastrenemia Present present absent  
Carcinoid tumors Small <1.5ccm >1.5 cms large  
Distant liver mets 2-5 10 22-75  
Outcome Never fatal Rarely fatal        25% 
Mortality. 
 
E cell hyperplasia or dysplasia present present absent  
Background mucosa CAG, 
  intestinal metaplasia 
Hypertrophy oxyntic glands,  
hyperplastuc  parietal cells 
normal  
Clinical management Endoscopic polypectomy Endoscopic  polypectomy Gastrectomy  
 
8. Neuroendocrine lung neoplasms 
1) Well differentiated neuroendocrine carcinoma Old name Carcinoid, 
Kulchistky tumor, typical carcinoid.   
Features- Prominent neuroendocrine organoid pattern, No 
cytologic atypia, Stippled salt pepper chromatin, Low mitotic 
activity, absence of tumor cell necrosis, neuroendocrine markers 
strong. These tumours account for 80%–90% of all carcinoid lung 
tumours. They can develop near the centre of the lung (known as 
central carcinoids) or toward the edges of the lung (known as 
peripheral carcinoids). Typical carcinoid tumours are well-
differentiated endocrine tumours that are benign or potentially 
malignant. They grow slowly but sometimes (in about 5% of cases) 
metastasize to the lymph nodes in the lung. They rarely spread to 
other lymph nodes or outside the chest. 
2) Moderately differentiated neuroendocrine carcinoma Atypical 
Carcinoid.  
Features- preservation of neuroendocrine growth pattern, 
increased cytologic atypia,prominent nucleoli, Moderately increased 
mitotic activity, frequent areas of comedonecrosis,retained 
expression of NE markers. 
3) Poorly differentiated neuroendocrine carcinoma. Old name- small 
cell carcinoma, oat cell carcinoma, kulchitky cell carcinoma, Large 
cell neuroendocrine carcinoma, undifferentiated small cell 
carcinoma.  
Features- Poorly developed neuroendocrine growth pattern, 
marked cytologic atypia, small or large cell morphology, High 
mitotic activity (>10 per 10 HPF), Extensive areas of necrosis.  
Small cell lung cancer (SCLC)-SCLC is also known as oat cell 
carcinoma and small cell carcinoma. It accounts for 15%–20% of all lung 
cancers. It has a strong association with tobacco smoking. Small cell lung 
cancer is the most aggressive of all lung cancers, and it usually 
progresses rapidly. SCLC shows neuroendocrine features, such as 
producing hormones that can cause signs and symptoms of disease 
outside the chest (called paraneoplastic syndromeparaneoplastic 
syndrome. A group of symptoms that occurs when substances released 
by cancer cells disrupt the normal function of nearby or distant organs 
or tissues.). 
Large cell neuroendocrine carcinoma (LCNEC)-LCNEC is a 
variant of large cell lung cancer, which is a type of non–small cell lung 
cancer. It is an aggressive type of neuroendocrine lung cancer.  
 
 
Other Neuroendocrine lung tumors- 
Pulmonary paraganglioma, 10 Pulmonary PNETs. Rare only three cases 
in literature. Small blue tumor, CD99 t11; 22 translocations. 
 
9. Conclusion 
In contradiction to the general assumption that 
NETs/carcinoids are extremely rare and benign slow-growingtumors, it 
is evident that they are far more common than previously thought and 
often display a poor prognosis due to widespread disease. Although 
diagnostic modalities such as SRS, PET and the combination of nuclear 
imaging techniques with anatomical imaging are useful inaccurate and 
early diagnosis, the critical requirement is the development of a plasma 
or genetic marker to predict or identify early lesions. Treatment with 
somatostatin analogues can palliate symptoms and possibly delay 
progression, but more efficient therapies are needed to regulate NET 
cell proliferation. Peptide receptor radiotherapy with somatostatin 
analogues or radiolabeled precursors of tumor amines and peptides 
have demonstrated therapeutic advance but their efficacy remains 
modest. To date, other growth factor antagonists, angiogenic and kinase 
inhibitors have demonstrated either minimal or limited efficacy 
.Increased knowledge about NET cell biology and the genetic 
characteristics of the tumors is the key to the further evolution of 
therapy. The dominant goal is the need to develop an early diagnostic 
test and to establish a targeted therapeutic strategy as well as a rational 
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